TABLE OF CONTENTS
1. Background 2. Market Analysis 3. Internal Assessment 4. Strategic Initiatives 5. Health, Safety, and Environment Implementation KPIs 6. Stakeholder Management 7. Health, Safety, and Environment Best Practices 8. Health, Safety, and Environment Deliverables 9. Regulatory Compliance Enhancement 10. Portfolio Realignment for Emerging Markets 11. Health, Safety, and Environment (HSE) Program Implementation 12. Additional Resources 13. Key Findings and Results
Consider this scenario: A leading pharmaceutical company, aiming to address the health, safety, and environment concerns in emerging economies, faces a strategic challenge in expanding its market footprint.
The organization is grappling with a 20% decline in market share due to stringent regulatory environments, and intense competition from generic drug manufacturers. Additionally, internal challenges including R&D inefficiencies and a misaligned product portfolio exacerbate the situation. The primary strategic objective is to penetrate and establish a significant presence in emerging markets by overcoming regulatory hurdles and enhancing product competitiveness.
The organization, despite its robust product lineup and strong brand recognition, finds itself at a crossroads due to evolving global health priorities and a rapidly shifting pharmaceutical landscape. The declining market share in the face of generic competition and regulatory complexities underscores the urgent need for strategic realignment and innovation.
The pharmaceutical industry is witnessing significant growth, driven by increasing healthcare expenditures and demand for innovative drugs. However, this growth is accompanied by challenges, including regulatory scrutiny and competitive pressures.
Analyzing the competitive forces reveals:
Emerging trends such as personalized medicine and digital health are reshaping the industry. Major changes include:
The STEER analysis highlights the significance of Socio-cultural, Technological, Economic, Environmental, and Regulatory factors in shaping strategic decisions. For instance, technological advancements in drug discovery and the socio-cultural shift towards preventive healthcare present new opportunities for growth.
For a deeper analysis, take a look at these Market Analysis best practices:
The organization's strengths lie in its global footprint and a diverse product portfolio, yet it struggles with R&D productivity and adapting to digital transformation.
SWOT Analysis
Strengths include a strong global brand and extensive distribution network. Opportunities emerge from growing demand in emerging markets and digital health trends. Weaknesses are evident in slow R&D processes and a product portfolio not fully aligned with emerging market needs. External threats include regulatory challenges and the rapid rise of generic drugs.
Gap Analysis
The Gap Analysis reveals discrepancies between current capabilities in navigating regulatory environments and the agility needed to adapt to fast-changing global health priorities. Bridging these gaps, particularly in R&D and regulatory compliance, is imperative for successful market penetration in emerging economies.
Jobs To Be Done (JTBD) Analysis
The JTBD Analysis indicates that patients in emerging markets require affordable, accessible, and efficacious medicines. The company needs to realign its product development and marketing strategies to address these fundamental jobs effectively.
KPIS are crucial throughout the implementation process. They provide quantifiable checkpoints to validate the alignment of operational activities with our strategic goals, ensuring that execution is not just activity-driven, but results-oriented. Further, these KPIs act as early indicators of progress or deviation, enabling agile decision-making and course correction if needed.
These KPIs offer insights into the effectiveness of strategic initiatives, particularly in achieving market penetration and alignment with emerging market needs. Tracking these metrics closely will enable timely adjustments to the strategy, ensuring the achievement of strategic goals.
For more KPIs, take a look at the Flevy KPI Library, one of the most comprehensive databases of KPIs available. Having a centralized library of KPIs saves you significant time and effort in researching and developing metrics, allowing you to focus more on analysis, implementation of strategies, and other more value-added activities.
Learn more about Flevy KPI Library KPI Management Performance Management Balanced Scorecard
Success hinges on the engagement and support of stakeholders including regulatory bodies, local healthcare providers, and the R&D team.
Stakeholder Groups | R | A | C | I |
---|---|---|---|---|
Regulatory Bodies | ⬤ | |||
Local Healthcare Providers | ⬤ | |||
R&D Team | ⬤ | |||
Patients | ⬤ | |||
Local Governments | ⬤ |
We've only identified the primary stakeholder groups above. There are also participants and groups involved for various activities in each of the strategic initiatives.
Learn more about Stakeholder Management Change Management Focus Interviewing Workshops Supplier Management
To improve the effectiveness of implementation, we can leverage best practice documents in Health, Safety, and Environment. These resources below were developed by management consulting firms and Health, Safety, and Environment subject matter experts.
Explore more Health, Safety, and Environment deliverables
The organization adopted the Regulatory Impact Analysis (RIA) framework to enhance its approach to regulatory compliance. RIA is a systematic approach to critically assessing the positive and negative effects of proposed and existing regulations. It proved invaluable in understanding how to navigate the complex regulatory environments of emerging markets. By analyzing the impact of regulations on the organization's operations, the team was able to prioritize compliance efforts effectively.
Following this framework, the organization implemented the following steps:
The organization also utilized the PESTEL Analysis to complement the RIA framework, examining the Political, Economic, Social, Technological, Environmental, and Legal factors that could influence regulatory compliance efforts. This dual-framework approach enabled the organization to not only anticipate regulatory challenges but also to integrate compliance seamlessly into its market penetration strategy.
The results of implementing these frameworks were significant. The organization successfully navigated the regulatory environments of several key emerging markets, reducing the time-to-market for new drugs by 30%. This strategic approach to regulatory compliance enhanced the company's reputation with regulatory bodies and facilitated smoother market entry and expansion processes.
To realign its product portfolio for emerging markets, the organization turned to the Value Chain Analysis framework. This framework, developed by Michael Porter, focuses on dissecting an organization's activities to understand where value is added and how it can be maximized. This analysis was particularly useful for understanding how the organization's internal capabilities could be realigned to develop and deliver products that meet the unique needs of emerging markets.
In implementing the Value Chain Analysis, the organization took the following actions:
Additionally, the organization employed the Resource-Based View (RBV) to assess its internal resources and capabilities and determine how they could be leveraged or realigned to support the strategic initiative of portfolio realignment. By focusing on core competencies, the organization was able to identify new product development opportunities that aligned with market demands.
As a result of these strategic efforts, the organization launched several new products tailored to the needs of emerging markets, leading to a 25% increase in sales within these regions. The successful realignment of the product portfolio not only improved market penetration but also strengthened the organization's competitive position in these strategically important markets.
The organization chose to implement the Triple Bottom Line (TBL) framework for its Health, Safety, and Environment program. The TBL framework encourages businesses to look beyond profits to include social and environmental considerations in their decision-making processes. This framework was instrumental in structuring the HSE program to ensure it not only complied with local regulations but also contributed positively to the communities and environments in which the organization operated.
Utilizing the TBL framework, the organization undertook the following steps:
The integration of the TBL framework into the HSE program led to the achievement of several key outcomes. The organization saw a 40% reduction in workplace incidents and a significant improvement in environmental sustainability metrics. Furthermore, the enhanced focus on community health and safety led to stronger community relations and support for the organization's operations in emerging markets. This holistic approach to HSE not only improved compliance but also positioned the organization as a responsible and preferred partner in its new markets.
Here are additional best practices relevant to Health, Safety, and Environment from the Flevy Marketplace.
Here is a summary of the key results of this case study:
The strategic initiatives undertaken by the organization have yielded significant positive outcomes, notably in regulatory compliance, market penetration, and environmental and social responsibility. The reduction in time-to-market for new drugs by 30% is a clear indicator of success in navigating complex regulatory landscapes, which was a critical barrier to entry in emerging markets. The 25% increase in sales underscores the effectiveness of the portfolio realignment strategy, demonstrating that the organization has successfully adapted its offerings to meet the specific needs of these markets. The implementation of the Triple Bottom Line framework has not only improved operational safety and environmental sustainability but also enhanced community relations, contributing to the organization's long-term success in these regions.
However, while these results are commendable, there are areas for improvement. The report does not detail the impact of these initiatives on overall market share, which remains a critical measure of success in the competitive pharmaceutical landscape. Furthermore, the integration of digital health technologies was identified as an opportunity but not fully addressed in the strategic initiatives. Exploring digital health solutions could further enhance product competitiveness and patient outcomes in emerging markets.
Recommendations for next steps include a focused effort on measuring and increasing overall market share in emerging markets, leveraging the positive outcomes achieved thus far. The organization should also invest in digital health technologies, such as telemedicine and mobile health applications, to complement its current product offerings. This could include partnerships with technology companies to accelerate development and adoption. Additionally, continuous engagement with local communities and stakeholders should be maintained to ensure the sustainability of the organization's operations and its positive impact on society.
Source: Global Market Penetration Strategy for Pharma in Emerging Economies, Flevy Management Insights, 2024
Leverage the Experience of Experts.
Find documents of the same caliber as those used by top-tier consulting firms, like McKinsey, BCG, Bain, Deloitte, Accenture.
Download Immediately and Use.
Our PowerPoint presentations, Excel workbooks, and Word documents are completely customizable, including rebrandable.
Save Time, Effort, and Money.
Save yourself and your employees countless hours. Use that time to work on more value-added and fulfilling activities.
![]() |
Download our FREE Strategy & Transformation Framework Templates
Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more. |